Carnegie acted as a manager in the exercise of warrants in BerGenBio. 93.6 % of the outstanding warrants were exercised, raising gross proceeds of approximately NOK 139 million.
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone therapy for aggressive diseases, including cancer and severe respiratory infections.